Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Challenges in Cancer-Associated Thrombosis
share announcement

Challenges in Cancer-Associated Thrombosis

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 5764

Special Issue Editor

Dr. Remedios Otero-Candelera

E-Mail Website
Guest Editor
1. Medical Surgical Unit of Respiratory Diseases, Hospital Universitario Virgen del Rocio, Seville, Spain
2. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, CIBERES, Spain
Interests: venous thromboembolism; cancer-associated thrombosis; pulmonary embolism; chronic thromboembolic pulmonary hypertension; biomarkers

Special Issue Information

Dear Colleagues,

Cancer patients are at increased risk of venous thromboembolism (VTE). Furthermore, VTE incidence associated with cancer has increased due to VTE detection in routine-imaging testing for cancer staging. VTE in cancer presents an increased risk of recurrence, bleeding, and mortality. The updated guidelines recommend either apixaban, rivaroxaban, or low molecular weight heparin (LMWH) for thromboprophylaxis in selected high-risk outpatients with cancer without a contraindication to anticoagulation or drug–drug interactions. Although a VTE risk score for ambulatory patients receiving cancer chemotherapy has been validated, efforts to improve the accuracy of this tool still continue. Guidelines also consider rivaroxaban, edoxaban or LMWH as options for the treatment of VTE in cancer patients. LMWH, edoxaban, and rivaroxaban are preferred for long-term anticoagulation (at least 6 months). It is considered anticoagulation beyond 6 months in select patients with metastatic disease or those receiving chemotherapy, but biomarkers that guide us on the duration of VTE treatment in cancer patients are not yet established.

In this Special Issue, articles about direct oral anticoagulant drugs in cancer patients and about different approaches to select cancer patients for thromboprophylaxis or to decide the suitable anticoagulation duration will be reported.

Dr. Remedios Otero-Candelera
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer-associated thrombosis
  • thromboprophylaxis
  • duration of anticoagulation
  • venous thromboembolism diseases
  • low molecular weight heparin
  • rivaroxaban
  • apixaban
  • edoxaban

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

15 pages, 2914 KiB  
Article
Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
by Remedios Otero, Aurora Solier-López, Verónica Sánchez-López, Julia Oto, Elena Arellano, Samira Marín, Luis Jara-Palomares, Teresa Elías, María Isabel Asencio, Isabel Blasco-Esquivias, María Rodríguez de la Borbolla, José María Sánchez-Díaz, Macarena Real-Domínguez, Emilio García-Cabrera, Francisco Javier Rodríguez-Martorell and Pilar Medina
Cancers 2022, 14(11), 2771; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14112771 - 02 Jun 2022
Cited by 4 | Viewed by 1968
Abstract
The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurrence after anticoagulation [...] Read more.
The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurrence after anticoagulation discontinuation. Blood samples were obtained when patients stopped the anticoagulation, at 21 days and at 90 days. In each sample we assessed different coagulation-related biomarkers: D-dimer (DD), high-sensitivity C-reactive protein (hs-CRP), P-selectin (PS), phospholipids, soluble tissue factor, factor VIII and the thrombin generation test. It was evaluated 325 CAT patients and 166 patients were included in the study, mean age 64 ± 17 years. VTE recurrence until 6 months after stopping anticoagulation treatment was 9.87% [95% confidence interval (CI): 6–15]. The biomarkers sub-distribution hazard ratios were 6.32 for ratio DD basal/DD 21 days > 2 (95% CI: 1.82–21.90), 6.36 for hs-CRP > 4.5 (95% CI: 1.73–23.40) and 5.58 for PS > 40 (95% CI: 1.46–21.30) after 21 days of stopping anticoagulation. This is the first study that has identified the DD ratio, hs-CRP and PS as potential biomarkers of VTE recurrence in cancer patients after the discontinuation of anticoagulation treatment. A risk-adapted strategy may allow the identification of the optimal time to withdraw the anticoagulation in each CAT patient. Full article
(This article belongs to the Special Issue Challenges in Cancer-Associated Thrombosis)
►▼ Show Figures

Figure 1

Other

Jump to: Research

16 pages, 502 KiB  
Systematic Review
A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology
by Federico Romano, Giovanni Di Lorenzo, Guglielmo Stabile, Mariateresa Mirandola, Stefano Restaino, Patrizia Ianniello, Giuseppe Mirenda and Giuseppe Ricci
Cancers 2022, 14(10), 2439; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14102439 - 15 May 2022
Cited by 4 | Viewed by 3181
Abstract
(1) Background: This review aimed to summarize the indications for venous thromboembolic (VTE) events’ prophylaxis in a gynecological cancer population, according to the most recent guidelines. (2) Methods: A systematic review of the guidelines in PubMed, SCOPUS, Web of Science, EMBASE, and CINHAL [...] Read more.
(1) Background: This review aimed to summarize the indications for venous thromboembolic (VTE) events’ prophylaxis in a gynecological cancer population, according to the most recent guidelines. (2) Methods: A systematic review of the guidelines in PubMed, SCOPUS, Web of Science, EMBASE, and CINHAL regarding VTE prevention in gynecological cancer patients was conducted according to PRISMA criteria. We compared the recommendations given by oncological and hematological societies regarding VTE prevention in gynecological cancer patients published from January 2010 through March 2021. We searched for the following keywords: “venous thromboembolism prevention”, “cancer”, and “guidelines”. The AGREE II checklist was used to critically analyze the guidelines’ quality. (3) Results: There were 1003 documents available; 14 met the inclusion criteria, 5 were excluded and, eventually, the guidelines of 10 societies were evaluated. (4) Conclusions: The guidelines agree that low-molecular-weight heparin (LMWH) and fondaparinux achieve better results in VTE prevention in gynecological cancer patients. Direct oral anticoagulants (DOACs) can be used to prevent VTE in outpatients and high-risk medical patients after discharge. VTE risk scores should be applied to all oncological patients to identify those who would benefit from a prevention program. More attention should be paid to mechanical prophylactic methods due to the high bleeding risk of gynecological cancer patients. Full article
(This article belongs to the Special Issue Challenges in Cancer-Associated Thrombosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop